Literature DB >> 150307

beta(1 leads to 3) Glucan-mediated augmentation of alloreactive murine cytotoxic T-lymphocytes in vivo.

J Hamuro, M Röllinghoff, H Wagner.   

Abstract

Five different beta(1 leads to 3) glucans were tested for immune adjuvant activity on the in vivo induction of alloreactive murine cytotoxic T-lymphocytes (CTL). The beta(1 leads to 3) glucans, lentinan, pachyman, pachymaran, and two differently substitute hydroxyethylated pachymans strongly enhanced the in vivo generation of alloreactive CTL. The augmenting effect of i.p.-administered beta(1 leads to 3) glucans exhibited a clear dose-response relationship and was strictly dependent on the injection schedule used. Injection of high doses of beta(1 leads to 3) glucans as well as the injection during the late phase of the immune response markedly suppressed the magnitude of the lytic CTL activity induced. When the optimal conditions for enhanced CTL responses were chosen, the augmented CTL activity within spleen cells and mesenteric lymph node cells persisted for more than 25 days. Since beta(1 leads to 3) glucans are chemically defined substances without obvious toxic side effects, they may be of potential use to augment in vivo antigen-specific T-cell responses.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 150307

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Lentinan prolonged survival in patients with gastric cancer receiving S-1-based chemotherapy.

Authors:  Kenji Ina; Ryuichi Furuta; Takae Kataoka; Satoshi Kayukawa; Takashi Yoshida; Takaya Miwa; Yoshitaka Yamamura; Yuuki Takeuchi
Journal:  World J Clin Oncol       Date:  2011-10-10

2.  Immune-stimulating properties of polysaccharides from Phellodendri cortex (Hwangbek).

Authors:  J I Park; J K Shim; J W Do; S Y Kim; E K Seo; H J Kwon; T K Lee; J K Kim; D Y Choi; C H Kim
Journal:  Glycoconj J       Date:  1999-03       Impact factor: 2.916

3.  Curative effects of combination therapy with lentinan and interleukin-2 against established murine tumors, and the role of CD8-positive T cells.

Authors:  M Suzuki; T Kikuchi; F Takatsuki; J Hamuro
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

4.  Glucan as an adjuvant for a murine Babesia microti immunization trial.

Authors:  J L Benach; G S Habicht; T W Holbrook; J A Cook
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

5.  Induction of cytotoxic peritoneal exudate cells by T-cell immune adjuvants of the beta(1 leads to 3) glucan-type lentinan and its analogues.

Authors:  J Hamuro; M Röllinghoff; H Wagner
Journal:  Immunology       Date:  1980-04       Impact factor: 7.397

Review 6.  Molecular basis for Poria cocos mushroom polysaccharide used as an antitumour drug in China.

Authors:  Xiulian Li; Yanli He; Pengjiao Zeng; Yong Liu; Meng Zhang; Cui Hao; Hua Wang; Zhihua Lv; Lijuan Zhang
Journal:  J Cell Mol Med       Date:  2018-11-15       Impact factor: 5.310

Review 7.  The use of lentinan for treating gastric cancer.

Authors:  Kenji Ina; Takae Kataoka; Takafumi Ando
Journal:  Anticancer Agents Med Chem       Date:  2013-06       Impact factor: 2.505

8.  Phellinus linteus Extract Augments the Immune Response in Mitomycin C-Induced Immunodeficient Mice.

Authors:  Shintaro Matsuba; Hideo Matsuno; Masahiro Sakuma; Yasuhiro Komatsu
Journal:  Evid Based Complement Alternat Med       Date:  2008-03       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.